FDA launches initiative to accelerate rare disease drugs
The US Food and Drug Administration (FDA), a division within the US Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to accelerate the development of drugs and biologics for rare diseases.
According to the regulator, the initiative will develop an optimised, fit-for-purpose framework that reflects the realities of rare disease drug development by considering the nuances of each disease, patient needs, product type and the evidence that can be realistically generated in small patient populations.
“Americans with rare diseases cannot afford a regulatory system that treats every condition the same,” said HHS Secretary Robert F Kennedy, Jr. “Under President Trump, FDA is rethinking rare disease drug development by putting patients at the centre and matching regulatory requirements to the realities of small patient populations. We will remove unnecessary barriers, embrace cutting-edge science, and accelerate promising treatments while upholding FDA’s rigorous standards.”
Only around 5% of rare conditions currently have an FDA-approved treatment. To address this, the FDA is committed to the following:
- Providing greater clarity, consistency, and predictability in regulatory decision-making through tailored guidance and transparent communication.
- Embedding the patient’s voice both early, and at clearly defined milestones, in the drug development and review process.
- Further leveraging external expertise to support customisation of regulatory review.
- Building shared resources, robust training, and institutional knowledge on rare disease drug development and review.
- Applying risk-based approaches, particularly to chemistry, manufacturing, and controls review and pre-approval inspections.
- Championing the use of cutting-edge science, novel methods and innovative statistical approaches in rare disease drug development.
The initiative is led by the FDA’s Rare Disease Innovation Hub, partnering with the Office of the Commissioner, the Center for Biologics Evaluation and Research, and the Center for Drug Evaluation and Research.